NYSE · Finance, Insurance & Real Estate · Hospital & medical service plans
$65.58−$1.87 (−2.77%) on the dayAs of the close; data may be delayed.
CNC price, last 12 months
$76.01$31.80$65.58
Daily closes over the last 260 trading sessions: +74.6%. Highest close $76.01 on , lowest $31.80 on . Market data may be delayed.
Key stats
Previous close
$67.45
Open
$67.64
Day range
$63.91 – $68.09
52-week range
$31.63 – $78.08
Volume
5.5M
Avg volume (20 days)
6.4M
Market cap
$35.3B
Performance
1W−10.5%
1M−10.5%
3M−2.9%
6M+7.8%
YTD+55.0%
1Y+77.4%
vs S&P 500, 1Y+72.2 pts
Technicals and fundamentals
About Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.
Chart CNC with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full CNC chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 26 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.
Technicals
RSI (14)40.0mid-range
vs 50-day average−5.4%
vs 200-day average+11.3%price between averages
MACDBelow signal
Daily range (ATR)5.4%average true range, % of price
52w low $31.6352w high $78.08
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)22.21.60x Finance, Insurance & Real Estate median (13.9)
P/E (forward)11.8
PEG0.79
Price / sales0.16
Price / book1.46
EV / EBITDA—
P/E since Jun 112.4 – 25.9
Company figures as of Nov 19, 2026.
Analysts
ConsensusBuy2.4 on 1 (strong buy) to 5 (strong sell)
Analysts18
Average target$76.00+19.2% from today
Price targets are opinions and tend to lean optimistic.
Earnings
Next results, expectedaround Feb 5, 2027 (in 77 days)A year after its Feb 6, 2026 results release; the last came Oct 27, 2026. An estimate from its SEC filings, not a date the company announced.
Dividends & splits
No dividends on record.
Splits
Feb 7, 20192-for-1
Feb 20, 20152-for-1
Dec 20, 20042-for-1
Seasonality
-0.0
J
-1.1
F
-5.7
M
+12.1
A
-1.0
M
+1.7
J
-5.6
J
+0.9
A
+2.7
S
+2.6
O
+3.4
N
+3.2
D
Average return in each calendar month, Oct 31, 2021 to Oct 31, 2026. 6 years is 6 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Year by year
Year
J
F
M
A
M
J
J
A
S
O
N
D
Year
2026
+5
+4
−27
+64
+11
+8
−3
+3
−3
+10
+66%
2025
+6
−9
+4
−1
−6
−4
−52
+11
+23
−1
+11
+5
−32%
2024
+1
+4
+0
−7
−2
−7
+16
+2
−5
−17
−4
+1
−18%
2023
−7
−10
−8
+9
−9
+8
+1
−9
+12
+0
+7
+1
−10%
2022
−6
+6
+2
−4
+1
+4
+10
−3
−13
+9
+2
−6
0%
2021
+14
+0
+15
+32%
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
Financials
As reported in the company's SEC filings. Latest: Q3 FY2026, ended Sep 30, 2026.
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
98.75% year-over-year gain with Momentum Score A; positioned as leading healthcare services player serving government-sponsored programs; recent 6.4% weekly decline presents momentum buying opportunity
Strong operational cash flow of ~$8 billion, significant debt reduction (debt-to-capital ratio improved from 46.5% to 41.6%), successful monetization of receivables, and stock gaining 58.2% year-to-date. Company maintains Zacks Rank #1 (Strong Buy) with forward P/E of 12.48 below industry average.
As a major ACA marketplace player, Centene would benefit from restored government subsidies and healthcare cost inflation. The company experienced significant member churn in 2026 but stands to recover if subsidies are reinstated and members return to coverage.
Stock gained 98.75% over the past year with a Momentum Score of A, indicating strong long-term performance despite a 6.4% weekly decline. The pullback is viewed as a buying opportunity within a strong uptrend.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.